Rxivist logo

Identifying SARS-CoV-2 entry inhibitors through drug repurposing screens of SARS-S and MERS-S pseudotyped particles

By Catherine Z Chen, Miao Xu, Manisha Pradhan, Kirill Gorshkov, Jennifer Petersen, Marco Straus, Wei Zhu, Paul Shinn, Hui Guo, Min Shen, Carleen Klumpp-Thomas, Samuel G. Michael, Joshua Zimmerberg, Wei Zheng, Gary Whittaker

Posted 11 Jul 2020
bioRxiv DOI: 10.1101/2020.07.10.197988 (published DOI: 10.1021/acsptsci.0c00112)

While vaccine development will hopefully quell the global pandemic of COVID-19 caused by SARS-CoV-2, small molecule drugs that can effectively control SARS-CoV-2 infection are urgently needed. Here, inhibitors of spike (S) mediated cell entry were identified in a high throughput screen of an approved drugs library with SARS-S and MERS-S pseudotyped particle entry assays. We discovered six compounds (cepharanthine, abemaciclib, osimertinib, trimipramine, colforsin, and ingenol) to be broad spectrum inhibitors for spike-mediated entry. This work should contribute to the development of effective treatments against the initial stage of viral infection, thus reducing viral burden in COVID-19 patients. ![Figure][1]</img> ### Competing Interest Statement The authors have declared no competing interest. [1]: pending:yes

Download data

  • Downloaded 1,338 times
  • Download rankings, all-time:
    • Site-wide: 24,391
    • In pharmacology and toxicology: 132
  • Year to date:
    • Site-wide: 73,090
  • Since beginning of last month:
    • Site-wide: 172,837

Altmetric data

Downloads over time

Distribution of downloads per paper, site-wide